MP470, a Novel Receptor Tyrosine Kinase Inhibitor, in Combination With Erlotinib Inhibits the HER Family/Pi3k/Akt Pathway and Tumor Growth in Prostate Cancer

BMC Cancer - United Kingdom
doi 10.1186/1471-2407-9-142
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Acetylshikonin Inhibits Colorectal Cancer Growth via PI3K/Akt/mTOR Signaling Pathway

Chinese Medicine
2018English

PCC0208027, a Novel Tyrosine Kinase Inhibitor, Inhibits Tumor Growth of NSCLC by Targeting EGFR and HER2 Aberrations

Scientific Reports
Multidisciplinary
2019English

Combination of Ruthenium Complex and Doxorubicin Synergistically Inhibits Cancer Cell Growth by Down-Regulating PI3K/AKT Signaling Pathway

Frontiers in Oncology
Cancer ResearchOncology
2020English

UNBS5162 Inhibits Colon Cancer Growth via Suppression of PI3K/Akt Signaling Pathway

Medecine/Sciences
BiochemistryMedicineGeneticsMolecular Biology
2018English

Novel HER2 Selective Tyrosine Kinase Inhibitor, TAK-165, Inhibits Bladder, Kidney and Androgen-Independent Prostate Cancer in Vitro and in Vivo

International Journal of Urology
Urology
2006English

Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer

Clinical Cancer Research
Cancer ResearchOncology
2009English

BMP9 Inhibits the Growth of Breast Cancer Cells by Downregulation of the PI3K/Akt Signaling Pathway

Oncology Reports
MedicineCancer ResearchOncology
2018English

Corrigendum: DT-13 Inhibits Proliferation and Metastasis of Human Prostate Cancer Cells Through Blocking PI3K/Akt Pathway

Frontiers in Pharmacology
Pharmacology
2020English

Tyrosine Kinase Signalling in Breast Cancer: ErbB Family Receptor Tyrosine Kinases

Breast Cancer Research
Cancer ResearchOncology
2000English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy